Abstract 109P
Background
With 18F-FDG PET/CT, tumor uptake intensity and textural features have been associated with outcome in several types of cancer. This study was to evaluate the prognostic value of pretreatment 18F-FDG PET/CT textural parameters in patients with primary metastatic colorectal cancer (CRC).
Methods
All patients (n = 104) who had had a pretreatment image of 18F-FDG PET/CT at our Hospital from January 2009 to December 2015 were included. Volumes of interest (VOIs) were drawn freehand around the tumor, and texture analysis was conducted on both CT and PET images within the same VOIs. A total of 35 features were extracted and analyzed. Univariate and multivariate analyses (logistic regression) were conducted to assess the prognostic value of textural parameters. Moreover, radiomics score (rad-score) was constructed using logistic regression. A multivariate logistic regression model was then used to establish a nomogram including the rad-score and other clinicopathological features.
Results
The results of univariate analysis showed that 18 textural parameters such as skewness and kurtosis were significantly associated with survival. In multivariate model, 17 textural parameters were shown to be able to predict PFS, including skewness (HR 2.777, p < 0.001), kurtosis (HR 0.441, p < 0.001), entropy (HR 1.704, p = 0.014), homogeneity (HR 0.548, p = 0.006), SRE (HR 1.853, p = 0.005), LRE (HR, p = 0.005), HGRE (HR 1.616, p = 0.036), LZE (HR 0.597, p = 0.018), LGZE (HR 0.439, p < 0.001) and HGZE (HR 2.085, p = 0.001). In addition, 8 textural parameters such as skewness (HR 4.475, p < 0.001), kurtosis (HR 0.377, p < 0.001), SRHGE (HR 2.062, p = 0.005) and LRLGE (HR 0.475, p = 0.003), were revealed to be independent predictors of OS among our population.
Conclusions
The texture analysis of the baseline 18F-FDG PET/CT appears to be a potential tool to predict outcomes of patients with primary metastatic CRC. However, prospective studies with a large population are needed to confirm the present findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract